Fig. 2.

L2-Cmu does not perturb glucose homeostasis in aged mice. a–d Glucose and insulin tolerance in 24-mo-old female and male mice is not adversely effected by 6 mo mAb treatment (n = 12 per group, per sex). e–h Chronic L2-Cmu treatment led to a non-significant (main effect, P = 0.097), numerical increase in plasma IGF-1 level in old females [Young (n = 8), Old Con (n = 16), and Old mAb (n = 15)], while no significant difference was observed for IGF-1 levels in male mice [Young (n = 8), Old Con (n = 15), and Old mAb (n = 16)]. Likewise, insulin levels were not significantly different in female [Young (n = 16), Old Con (n = 26), and Old mAb (n = 25)], or male mice [Young (n = 17), Old Con (n = 32), and Old mAb (n = 28)]. i, j L2-Cmu treatment in males and females prevented the age-related increase in hypothalamic IGF-1Rs and reduced cortical levels in males only (P ≤ 0.05), but had no effect on IGF-1Rs in lung or pancreas of either sex. k, l Further, L2-Cmu treatment had no effect on InsR levels in examined tissues of either sex (n = 8 per group, per sex). Bars represent mean ± s.e.m. Dot plots overlaid on bar graphs represent individual data points. NS not significant. Different letters denote a significant difference between groups by Tukey HSD, P ≤ 0.05